Evaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluations

Table 2 Projected incremental increase in effectiveness when using annual community-wide versus school-based treatment

Effectiveness metric	Relative pre-control worm burden in adults	Incremental increase in effectiveness (relative increase in effectiveness)
Effectiveness metric	Relative pre-control worm burden in adults	Higher transmission setting	Lower transmission setting
Average number of worm-years averted per person	Low	306 (17%)	107 (15%)
	Medium	481 (30%)	155 (23%)
	High	948 (80%)	314 (59%)
Prevalent case years averted (per 100 individuals)	Low	146 (83%)	176 (70%)
	Medium	168 (124%)	223 (99%)
	High	237 (303%)	305 (258%)
Heavy case years averted (per 100 individuals)	Low	27.1 (23%)	8.1 (12%)
	Medium	44.5 (43%)	11.4 (18%)
	High	85.5 (118%)	26.7 (52%)

The scenarios for the relative pre-control burden in adults are shown in Fig. 2 (note they have the same age-weighted overall mean worm burden). The results assume a treatment coverage of 75% and 5% systematic non-compliance. The analysis was conducted with a five-year implementation period and a 15-year time horizon (i.e. looking at the effect of five years of treatment for 15 years)

ISSN: 1756-3305